{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T14:40:22Z","timestamp":1788273622862,"version":"build-2803163510"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Approximately 4.8\u00a0million people in the United States had opioid use disorder in 2024, with more than one hundred thousand experiencing an overdose death. Despite the established benefits of buprenorphine on morbidity and mortality, many patients may express an interest in discontinuing their medications for various reasons, including stigma surrounding addiction. There are limited studies describing how to navigate buprenorphine discontinuation. This commentary provides a practical approach to navigating buprenorphine discontinuation, using two case studies. Ideally, clinicians will develop a deep understanding of the patient\u2019s substance use journey, allowing them to understand both the internal and external factors driving their decision. Through this understanding, a clinician can develop a plan based on their well-being, safety, and risk factors for return to use. It is vital to reinforce that buprenorphine is a life-saving medication, can be continued life-long, and is a tool for recovery, not a barrier.<\/jats:p>","DOI":"10.1186\/s12954-025-01353-2","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T14:05:25Z","timestamp":1764943525000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Practical guidance for navigating buprenorphine discontinuation"],"prefix":"10.1186","volume":"23","author":[{"given":"Kento","family":"Sonoda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda B.","family":"Hilmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer K.","family":"Bello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"key":"1353_CR1","unstructured":"Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: Results from the 2024 National Survey on Drug Use and Health. Published July 2025. https:\/\/www.samhsa.gov\/data\/data-we-collect\/nsduh-national-survey-drug-use-and-health\/national-releases. Accessed July 28, 2025."},{"key":"1353_CR2","doi-asserted-by":"crossref","unstructured":"Spencer MR, Garnett MF, Mini\u00f1o AM. Drug overdose deaths in the United States, 2002\u20132022. NCHS Data Brief, no 491. Hyattsville, MD: National Center for Health Statistics. 2024.","DOI":"10.15620\/cdc:135849"},{"issue":"3","key":"1353_CR3","doi-asserted-by":"publisher","first-page":"137","DOI":"10.7326\/M17-3107","volume":"169","author":"MR Larochelle","year":"2018","unstructured":"Larochelle MR, Bernson D, Land T, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study. Ann Intern Med. 2018;169(3):137. https:\/\/doi.org\/10.7326\/M17-3107.","journal-title":"Ann Intern Med"},{"key":"1353_CR4","doi-asserted-by":"publisher","first-page":"m772","DOI":"10.1136\/bmj.m772","volume":"368","author":"LA Pearce","year":"2020","unstructured":"Pearce LA, Min JE, Piske M, et al. Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study. BMJ. 2020;368:m772. https:\/\/doi.org\/10.1136\/bmj.m772.","journal-title":"BMJ"},{"key":"1353_CR5","doi-asserted-by":"publisher","first-page":"e5945","DOI":"10.1136\/bmj.e5945","volume":"345","author":"GJ MacArthur","year":"2012","unstructured":"MacArthur GJ, Minozzi S, Martin N, et al. Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. BMJ. 2012;345:e5945. https:\/\/doi.org\/10.1136\/bmj.e5945.","journal-title":"BMJ"},{"key":"1353_CR6","doi-asserted-by":"publisher","first-page":"108207","DOI":"10.1016\/j.drugalcdep.2020.108207","volume":"215","author":"JA Barocas","year":"2020","unstructured":"Barocas JA, Gai MJ, Amuchi B, Jawa R, Linas BP. Impact of medications for opioid use disorder among persons hospitalized for drug use-associated skin and soft tissue infections. Drug Alcohol Depend. 2020;215:108207. https:\/\/doi.org\/10.1016\/j.drugalcdep.2020.108207.","journal-title":"Drug Alcohol Depend"},{"issue":"14","key":"1353_CR7","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1056\/NEJMp1917360","volume":"382","author":"ND Volkow","year":"2020","unstructured":"Volkow ND. Stigma and the toll of addiction. N Engl J Med. 2020;382(14):1289\u201390. https:\/\/doi.org\/10.1056\/NEJMp1917360.","journal-title":"N Engl J Med"},{"key":"1353_CR8","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jsat.2015.05.005","volume":"57","author":"LB Monico","year":"2015","unstructured":"Monico LB, Gryczynski J, Mitchell SG, Schwartz RP, O\u2019Grady KE, Jaffe JH. Buprenorphine treatment and 12-step meeting attendance: conflicts, compatibilities, and patient outcomes. J Subst Abuse Treat. 2015;57:89\u201395. https:\/\/doi.org\/10.1016\/j.jsat.2015.05.005.","journal-title":"J Subst Abuse Treat"},{"issue":"3","key":"1353_CR9","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1080\/00952990.2021.2003809","volume":"48","author":"MC Hazle","year":"2022","unstructured":"Hazle MC, Saxon AJ, Hill KP. Buprenorphine in safety-sensitive positions. Am J Drug Alcohol Abuse. 2022;48(3):255\u20139. https:\/\/doi.org\/10.1080\/00952990.2021.2003809.","journal-title":"Am J Drug Alcohol Abuse"},{"key":"1353_CR10","unstructured":"US. Department of Justice Civil Rights Division. ADA.gov. Accessed July 28, 2025. https:\/\/www.ada.gov"},{"issue":"1","key":"1353_CR11","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/add.15998","volume":"118","author":"JM Glanz","year":"2023","unstructured":"Glanz JM, Binswanger IA, Clarke CL, et al. The association between buprenorphine treatment duration and mortality: a multi-site cohort study of people who discontinued treatment. Addiction. 2023;118(1):97\u2013107. https:\/\/doi.org\/10.1111\/add.15998.","journal-title":"Addiction"},{"issue":"6","key":"1353_CR12","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1097\/ADM.0000000000001202","volume":"17","author":"MB Weimer","year":"2023","unstructured":"Weimer MB, Herring AA, Kawasaki SS, Meyer M, Kleykamp BA, Ramsey KS. ASAM clinical considerations: buprenorphine treatment of opioid use disorder for individuals using high-potency synthetic opioids. J Addict Med. 2023;17(6):632\u20139. https:\/\/doi.org\/10.1097\/ADM.0000000000001202.","journal-title":"J Addict Med"},{"issue":"6","key":"1353_CR13","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1097\/ADM.0000000000000789","volume":"15","author":"JE Zweben","year":"2021","unstructured":"Zweben JE, Sorensen JL, Shingle M, Blazes CK. Discontinuing methadone and buprenorphine: a review and clinical challenges. J Addict Med. 2021;15(6):454\u201360. https:\/\/doi.org\/10.1097\/ADM.0000000000000789.","journal-title":"J Addict Med"},{"issue":"6","key":"1353_CR14","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1080\/16066359.2022.2055002","volume":"30","author":"E Bowen","year":"2022","unstructured":"Bowen E, Irish A, LaBarre C, Capozziello N, Nochajski T, Granfield R. Qualitative insights in item development for a comprehensive and inclusive measure of recovery capital. Addict Res Theory. 2022;30(6):403\u201313. https:\/\/doi.org\/10.1080\/16066359.2022.2055002.","journal-title":"Addict Res Theory"},{"key":"1353_CR15","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.drugalcdep.2017.03.022","volume":"177","author":"CL Vilsaint","year":"2017","unstructured":"Vilsaint CL, Kelly JF, Bergman BG, Groshkova T, Best D, White W. Development and validation of a brief assessment of recovery capital (BARC-10) for alcohol and drug use disorder. Drug Alcohol Depend. 2017;177:71\u20136. https:\/\/doi.org\/10.1016\/j.drugalcdep.2017.03.022.","journal-title":"Drug Alcohol Depend"},{"key":"1353_CR16","unstructured":"Kumar R, Viswanath O, Saadabadi A. Buprenorphine. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; 2025 Jan-. Updated June 8, 2024. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK459126\/"},{"key":"1353_CR17","unstructured":"ReVIDA Recovery. How to Taper Off Suboxone. March 7, 2022. https:\/\/www.revidarecovery.com\/news\/how-to-taper-off-suboxone\/#:~:text=An%20additional%20rule%20is%20that,of%20buprenorphine%20(Suboxone\u00ae)"},{"issue":"3","key":"1353_CR18","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1097\/ADM.0000000000000738","volume":"15","author":"AD Ritvo","year":"2021","unstructured":"Ritvo AD, Calcaterra SL, Ritvo JI. Using extended release buprenorphine injection to discontinue sublingual buprenorphine: a case series. J Addict Med. 2021;15(3):252\u20134. https:\/\/doi.org\/10.1097\/ADM.0000000000000738.","journal-title":"J Addict Med"},{"key":"1353_CR19","doi-asserted-by":"publisher","DOI":"10.1177\/29767342241242242","author":"C Epland","year":"2024","unstructured":"Epland C, Pals H, Hayden J. Buprenorphine enhanced taper tolerability evaluation report (BETTER): a case series. Subst Use Addict J. 2024. https:\/\/doi.org\/10.1177\/29767342241242242.","journal-title":"Subst Use Addict J"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-025-01353-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-025-01353-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-025-01353-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T22:20:50Z","timestamp":1768342850000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12954-025-01353-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1353"],"URL":"https:\/\/doi.org\/10.1186\/s12954-025-01353-2","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]},"assertion":[{"value":"16 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"NA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5"}}